OKUR

OnKure Therapeutics Inc

2.53

Nov 05 • 3:59 PM ET -0.06 (-2.51%)

2.53

Aftermarket • 5:00 PM ET +0.00 (0.20%)

Healthcare Biotechnology USA Micro NASD

Nov 04, 6:45 PMOnKure reports Q3 2026 results with non-GAAP EPS -$0.36 (+67% YoY), beats EPS estimates, revenue $0 misses forecasts

Peers: RLAY CELC OLMA KZIA ARVN BDTX PVLA ACRV ZNTL TYRA

| Held by: VTI IWM VXF IWN VTWO TMED IWC BUSM DFAS AVSC

Scroll to Statements

Index	RUT
Market Cap	102.26M
Enterprise Value	-60.26M
Income	-61.85M
Sales	0.00M
Book/sh	3.89
Cash/sh	4.03
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	45
IPO	Apr 09, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.65
P/C	0.63
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	18.84
Current Ratio	18.84
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.77
EPS next Y	-1.58
EPS next Q	-0.45
EPS this Y	58.26%
EPS next Y	13.79%
EPS next 5Y	31.57%
EPS past 3/5Y	40.79% 11.29%
Sales past 3/5Y	- -
EPS Y/Y TTM	55.14%
Sales Y/Y TTM	-
EPS Q/Q	67.10%
Sales Q/Q	-
Earnings	Nov 04 AMC
EPS/Sales Surpr.	11.48% -100.00%

Insider Own	31.26%
Insider Trans	-0.01%
Inst Own	71.76%
Inst Trans	12.94%
ROA	-51.56%
ROE	-55.18%
ROIC	-39.08%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	3.46%
SMA50	-9.84%
SMA200	-29.93%
Trades

Shs Outstand	40.50M
Shs Float	27.84M
Short Float	4.98%
Short Ratio	4.89
Short Interest	1.39M
52W High	5.38 -53.07%
52W Low	2.01 25.62%
Volatility	7.85% 8.53%
ATR (14)	0.21
RSI (14)	46.86
Beta	0.19
Rel Volume	1.15
Avg Volume	283.08K
Volume	325,163

Perf Week	-3.63%
Perf Month	7.45%
Perf Quarter	-39.01%
Perf Half Y	-36.24%
Perf YTD	-12.93%
Perf Year	-15.83%
Perf 3Y	-96.76%
Perf 5Y	-96.82%
Perf 10Y	-
Recom	1.50
Target Price	13.67
Prev Close	2.59
Price	2.53
Change %	-2.51%

Consensus

Buy

Avg. Price Target

$13.67

Implied Upside

+441.4%

Analysts11incl. previous ratings

Rating Distribution4 Buy · 6 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Apr 30, 2025	Initiated	EEvercore ISI	Outperform
Dec 05, 2024	Initiated	LLeerink Partners	Outperform	$33	+1,206.9%
Oct 10, 2024	Initiated	OOppenheimer	Outperform	$35	+1,286.1%
Dec 15, 2023	Downgrade	LLeerink Partners	Outperform → Market Perform
Dec 15, 2023	Downgrade	JJefferies	Buy → Hold
Dec 15, 2023	Downgrade	HH.C. Wainwright	Buy → Neutral	$30 → $1.50	-40.6%
Dec 14, 2023	Downgrade	WWilliam Blair	Outperform → Mkt Perform
Dec 14, 2023	Downgrade	RRobert W. Baird	Outperform → Neutral	$28 → $3	+18.8%
Dec 14, 2023	Downgrade	PPiper Sandler	Overweight → Neutral	$25 → $4	+58.4%
Dec 14, 2023	Downgrade	LLadenburg Thalmann	Buy → Neutral
Dec 14, 2023	Downgrade	BBofA Securities	Buy → Underperform	$23 → $1.45	-42.6%
Nov 15, 2023	Initiated	WWilliam Blair	Outperform	$35.55	+1,307.9%
Aug 28, 2023	Initiated	HH.C. Wainwright	Buy	$30	+1,088.1%
Jul 03, 2023	Initiated	BBofA Securities	Buy
Sep 19, 2022	Resumed	HH.C. Wainwright	Buy	$31	+1,127.7%
Jan 27, 2022	Initiated	RRobert W. Baird	Outperform	$28	+1,008.9%
Dec 21, 2021	Initiated	HH.C. Wainwright	Buy	$28	+1,008.9%
Nov 22, 2021	Initiated	LLadenburg Thalmann	Buy	$45	+1,682.2%
May 04, 2021	Initiated	SSVB Leerink	Outperform	$25	+890.1%
May 04, 2021	Initiated	PPiper Sandler	Overweight	$45	+1,682.2%

Nov-04-26 04:05PM	OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights (GlobeNewswire)
Aug-31-26 08:00AM	OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-04-26 04:05PM	OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights (GlobeNewswire)
Jul-02-26 08:00AM	OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Ka Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 (GlobeNewswire)
May-05-26 04:05PM	OnKure Therapeutics Reports First Quarter 2026 Financial Results (GlobeNewswire) -9.96%
08:00AM	Loading…
Mar-27-26 08:00AM	OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Ka Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies (GlobeNewswire) -13.07%
Mar-12-26 04:05PM	OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) +7.39%
Nov-06-25 04:03PM	OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire) +5.33% -6.96%
Nov-04-25 04:05PM	OnKure Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.20%
Aug-12-25 04:05PM	OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire) +20.00%
May-06-25 07:30AM	OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -11.16%
Mar-10-25 04:05PM	OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-04-25 08:00AM	OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences (GlobeNewswire) +7.45%
Dec-10-24 07:00AM	OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 (GlobeNewswire) -8.47%
Nov-25-24 05:31PM	OnKure Announces New Date for Upcoming Investor Call (GlobeNewswire)
04:05PM	Loading…
Nov-05-24 04:05PM	OnKure to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire) +7.90%
Nov-01-24 05:30PM	OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -6.91%
Oct-07-24 04:32AM	OnKure and Reneo Pharmaceuticals complete merger (Pharmaceutical Technology)
Oct-04-24 04:57PM	OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million (GlobeNewswire) +5.20%
Oct-02-24 08:20PM	Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure (GlobeNewswire)
Aug-13-24 07:35AM	Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results (GlobeNewswire)
May-16-24 10:01AM	Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing (MT Newswires)
May-13-24 08:25AM	Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise (MT Newswires) -12.15%
07:35AM	Reneo Pharmaceuticals and OnKure Announce Proposed Merger (GlobeNewswire)
May-07-24 01:53PM	RPHM Stock Earnings: Reneo Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
07:35AM	Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results (GlobeNewswire)
Mar-28-24 12:53PM	RPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
07:35AM	Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update (GlobeNewswire)
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire)
Dec-21-23 04:13PM	These Stocks under $10 Are Poised To Explode (Insider Monkey)
10:19AM	Loading…
Dec-15-23 10:19AM	Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study (Zacks) +5.97%
Dec-14-23 12:35PM	Why Is Genetic Disease Focused Reneo Pharmaceuticals Stock Plummeting Today? (Benzinga) -82.71%
09:05AM	Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) (GlobeNewswire)
Nov-13-23 05:04PM	Reneo Pharmaceuticals Inc (RPHM) Reports Q3 2023 Financial Results (GuruFocus.com)
07:35AM	Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 07:50AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-25-23 07:50AM	Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings (GlobeNewswire)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey) -5.76%
Oct-09-23 07:50AM	Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) (GlobeNewswire)
Oct-06-23 08:30AM	Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit (GlobeNewswire) +11.47%
Aug-29-23 07:35AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.30%
Aug-10-23 07:35AM	Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results (GlobeNewswire)
07:31AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) stock price dropped 10% last week; private equity firms would not be happy (Simply Wall St.)
Jul-27-23 11:19AM	Bank of America Says These 2 Stocks Could Double Your Money Heres Why They Could Rally (TipRanks) +17.59%
Jun-30-23 08:25AM	Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum (GlobeNewswire)
Jun-26-23 08:25AM	Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices (GlobeNewswire)
Jun-15-23 12:44PM	Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023 (GlobeNewswire)
May-31-23 10:38AM	Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
08:00AM	Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
May-21-23 07:42PM	Insiders Pour $1 Million Each Into These 2 Strong Buy Stocks Heres Why Wall Street Thinks They Could Double (or More) (TipRanks)
May-12-23 06:00PM	MP Materials, Pitney Bowes See Activist Investor Action (Barrons.com)
May-11-23 07:45AM	Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results (GlobeNewswire) +6.02%
May-03-23 11:36PM	Reneo Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-27-23 07:30AM	Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-14-23 07:30AM	Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies (GlobeNewswire)
Mar-09-23 08:00AM	Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023 (GlobeNewswire)
Mar-03-23 06:07AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) largest shareholders are private equity firms who were rewarded as market cap surged US$33m last week (Simply Wall St.)
Feb-02-23 07:35AM	Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-31-23 07:35AM	Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD) (GlobeNewswire)
Dec-04-22 07:12AM	Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-08-22 07:35AM	Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-03-22 08:00AM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
Sep-14-22 06:02AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) biggest owners are private equity firms who got richer after stock soared 25% last week (Simply Wall St.) +8.24%
Sep-06-22 08:35AM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-29-22 07:35AM	Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting (GlobeNewswire)
Aug-09-22 08:00AM	Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results (GlobeNewswire) -5.26%
Aug-04-22 09:10AM	Insiders who bought in the last 12 months lose an additional US$83k as Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) drops to US$57m (Simply Wall St.) +14.89%
Aug-02-22 07:30AM	Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors (GlobeNewswire) -15.92%
Jul-26-22 09:52AM	Reneo Pharmaceuticals Says Metabolic Disorder Program To Enter Next Stage Of Development (Benzinga)
07:30AM	Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates (GlobeNewswire)
Jul-11-22 08:00AM	Reneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.84%
Jun-30-22 08:00AM	Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) (GlobeNewswire) +13.73%
Jun-20-22 08:33AM	Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Invest In Growth? (Simply Wall St.)
May-10-22 04:05PM	Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results (GlobeNewswire) +9.09%
Mar-23-22 04:05PM	Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-22 08:30AM	Reneo Pharmaceuticals Announces Senior Leadership Promotions (GlobeNewswire)
Feb-02-22 08:00AM	Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference (GlobeNewswire) -8.93%
Jan-24-22 08:00AM	Reneo Pharmaceuticals Announces Changes to its Board of Directors (GlobeNewswire)
Jan-10-22 11:55AM	We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate (Simply Wall St.)
Dec-22-21 11:04AM	3 Strong Buy Stocks Under $10 With Triple-Digit Upside Potential (TipRanks) +15.28%
Nov-11-21 04:05PM	Reneo Pharmaceuticals Reports Third Quarter 2021 Financial Results (GlobeNewswire) +9.08% +5.23%
Nov-01-21 04:05PM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire) +6.71%
Oct-14-21 08:00AM	Reneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001 (GlobeNewswire)
Oct-11-21 02:35PM	Here's What Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) Shareholder Ownership Structure Looks Like (Simply Wall St.)
08:00AM	Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer (GlobeNewswire)
Sep-28-21 08:26AM	Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease and other Genetic Mitochondrial Myopathies (GlobeNewswire)
Sep-09-21 09:12AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.69%
Aug-11-21 05:55AM	Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-28-21 08:00AM	Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study (GlobeNewswire)
Jul-12-21 09:30AM	We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate (Simply Wall St.) +5.29%
Jul-09-21 08:00AM	Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction (GlobeNewswire)
Jul-07-21 08:00AM	Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference (GlobeNewswire)
Jun-29-21 08:00AM	Reneo Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices (GlobeNewswire)
May-20-21 06:00AM	Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results (GlobeNewswire) +6.34%
May-19-21 06:00AM	Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire) +5.62%
Apr-13-21 08:14AM	The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug (Benzinga)
Apr-09-21 12:32PM	Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today (InvestorPlace)
Apr-08-21 09:42PM	Reneo Pharmaceuticals Announces Pricing of Initial Public Offering (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Saccomano Nicholas A	President and CEO	Sep 21 '26	Sale	2.97	87	259	11,160	Sep 23 04:54 PM
Leverone Jason A.	Chief Financial Officer	Sep 21 '26	Sale	2.97	302	898	18,500	Sep 23 04:52 PM
Saccomano Nicholas A	President and CEO	Jun 22 '26	Sale	4.40	86	378	11,247	Jun 24 07:29 PM
Leverone Jason A.	Chief Financial Officer	Jun 22 '26	Sale	4.40	303	1,332	18,802	Jun 24 07:27 PM
Saccomano Nicholas A	President and CEO	Mar 23 '26	Sale	4.16	86	357	7,333	Mar 24 06:57 PM
Leverone Jason A.	Chief Financial Officer	Mar 23 '26	Sale	4.16	301	1,251	16,000	Mar 24 06:56 PM
Saccomano Nicholas A	President and CEO	Dec 22 '25	Sale	2.97	87	258	7,419	Dec 23 08:09 PM
Leverone Jason A.	Chief Financial Officer	Dec 22 '25	Sale	2.97	302	896	16,301	Dec 23 08:08 PM

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

PresidentDr. Nicholas A. Saccomano Ph.D.

Chief Financial OfficerMr. Jason A. Leverone CPA

Senior VP of Business Development & DirectorDr. Isaac Manke Ph.D.

M.P.H.Dr. Samuel Agresta M.D.

Chief Scientific OfficerDr. Dylan Hartley Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OKUR

OnKure Therapeutics Inc

Upgrade your Finviz experience